

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/013956 A1

(51) International Patent Classification⁷: **A61K 31/155**,
31/4439, 9/28, A61P 3/10

Jnr [US/US]; GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

(21) International Application Number:
PCT/EP2004/008970

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(22) International Filing Date: 9 August 2004 (09.08.2004)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0318824.0 11 August 2003 (11.08.2003) GB

(71) Applicant (*for all designated States except US*): **SB PHARMCO PUERTO RICO INC.** [US/US]; The Prentice Hall Corp. System of P.R. Inc., c/o FGR Corporate Services Inc., BBV Tower, 8th Floor, 254 Munoz Rivera Avenue (PR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLES, Peter, John** [CA/CA]; GlaxoSmithKline Inc., 7333 Mississauga Road North, Mississauga, Ontario L5N 6L4 (CA). **MACKENZIE, Donald, Colin** [GB/US]; GlaxoSmithKline (CIDRA), Road 172 Km 9.1, Bo. Certenejas, Cidra, Puerto Rico, 00739-1975 (PR). **MUDD, Paul, Norman**,

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

[Continued on next page]

(54) Title: NOVEL COMPOSITION COMPRISING ROSIGLITAZONE AND ANOTHER ANTIDIABETIC AGENT

Dissolution Profiles for Examples 1 and 2 -
Compound A



(57) Abstract: An oral dosage form comprising an erodable core, which core comprises rosiglitazone or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, the core having a coating with one or more openings, characterised in that the coating is erodable under predetermined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine.

WO 2005/013956 A1

WO 2005/013956 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NOVEL COMPOSITION COMPRISING ROSIGLITAZONE AND ANOTHER ANTIDIABETIC AGENT

The present invention relates to an oral dosage form comprising 5-[4-[2-
5 (N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter
'Compound A') or a pharmaceutically acceptable salt or solvate thereof and
another antidiabetic agent, to a process for preparing such a dosage form and to
the use of such a dosage form in medicine.

The use of a coating to control the rate of release of an active agent has
10 received considerable attention and many different devices have been
developed for such a purpose. For example, International Patent Application,
Publication Number WO 01/05430 describes a drug delivery device that enables
the delivery of drug substances which exhibit pH dependent solubility, in
particular compounds that are more soluble at low pH levels (less than pH 2)
15 than at near neutral levels (greater than about pH 5). Such delivery devices are
characterised by the presence of a coating that is impermeable and insoluble in
the fluid of the environment of use.

International patent application, Publication Number WO 95/30422
describes a series of controlled-release dosage forms of azithromycin. In
20 particular, there is described a series of dosage forms that reduce the exposure
of the upper GI tract (e.g. the stomach) to high concentrations of azithromycin,
by the use of a pH dependent coating. Such dosage forms do not feature
openings through which release of the drug substance may occur.

US Patent Number 6,099,859 describes a controlled release tablet for the
25 delivery of an antihyperglycaemic drug, which comprises an osmotically active
drug-containing core and a semipermeable membrane, wherein the
semipermeable membrane is permeable to the passage of water and biological
fluids and is impermeable to the passage of the drug substance. The
semipermeable membrane contains at least one passageway for the release of
30 the antihyperglycaemic drug.

US Patent Number 5,543,155 describes a diffusion-osmotic controlled
drug release pharmaceutical composition comprising a one- or two-layer tablet
core containing hydroxypropyl methylcellulose, said core having a film-coat
comprising an ammonium methacrylate copolymer.

Additional devices that utilise a coating to control the rate of release of an active agent are discussed in US Patent Number 5,004,614. This patent
5 describes a tablet core provided with an outer coating that is substantially impermeable to environmental fluid. The said outer coating may be prepared from materials that are either insoluble or soluble in the environmental fluids. Where a soluble material is used, the coating is of sufficient thickness that the core is not exposed to environmental fluid before the desired duration of the
10 controlled release of the active agent has passed. Through this impermeable outer coating, one or more opening(s) has been created, so as to provide environmental fluids with an access route to the core. Therefore, upon ingestion of the coated tablet, gastro-intestinal fluid can enter the opening(s) and contact or penetrate the core, to release the active agent. The result is that the active
15 agent is released in a controlled manner out of the opening(s) only. The preferred geometry is such that there is a circular hole on the top and bottom face of the coated tablet. The opening(s) in question have an area from about 10 to 60 percent of the face area of the coated tablet. The rate of drug release is found to be directly related to the diameter of the opening(s) and to the solubility
20 of the matrix core and active agent, allowing the possibility for a variety of drug release profiles be it zero or first order release.

The substantially impermeable coatings of US 5,004,614 are not suitable for the controlled release of all active agents, especially pharmaceutically active weak bases or pharmaceutically acceptable salts and solvates thereof. Such
25 active agents exhibit a marked pH dependent solubility, *i.e.* they are more soluble at around pH 2, associated with regions found in the stomach, compared to their solubility in the generally neutral conditions of the small intestine, around pH 7.

International Patent Application, Publication Number WO 03/068195
30 discloses an oral dosage form comprising an erodable core which contains a pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof, such as Compound A, the core having a coating with one or more openings leading to the core, and the coating being erodable under predetermined pH conditions. This provides a beneficial means for

administration of a pharmaceutically active weak base or a pharmaceutically acceptable salt or solvate thereof, such as Compound A, where it is desirable that release of the active compound takes place in more than one pH environment, based on the finding that it is also beneficial for the coating to be erodable or soluble in a pH dependent manner.

We have now found that the oral dosage form described in International Patent Application Number WO 03/068195 may be beneficially used as a platform for the delivery of more than one active agent, such as, for example, Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent. To this end the said oral dosage form provides a beneficial means for delivering the other antidiabetic agent, where the antidiabetic agent has a narrow absorption window.

European Patent Application, Publication Number 0 306 228 A1 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity. One particular thiazolidinedione disclosed in EP 0 306 228 A1 is Compound A. International Patent Application, Publication Number WO 94/05659 discloses certain salts of Compound A including the maleate salt at Example 1 thereof. Compound A or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, may be prepared using known methods, for example those disclosed in EP 0 306 228 and WO 94/05659. The disclosures of EP 0 306 228 and WO 94/05659 are incorporated herein by reference.

Compound A is a pharmaceutically acceptable weak base.

Compound A and pharmaceutically acceptable salts or solvates thereof have useful pharmaceutical properties. In particular, Compound A or a salt or solvate thereof is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof; metabolic syndrome, impaired glucose tolerance and impaired fasting glucose.

International Patent Application, Publication Number WO 01/35941 describes certain fixed dose compositions comprising a thiazolidinedione, such as Compound A or a pharmaceutically acceptable derivative thereof and another antidiabetic agent such as metformin hydrochloride.

European Patent Number 0 861 666 describes pharmaceutical compositions comprising insulin sensitisers, such as pioglitazone or Compound A, and metformin.

International Patent Application, Publication Number WO 00/28989
5 describes various modified release pharmaceutical compositions comprising Compound A or a pharmaceutically acceptable salt or solvate thereof, and another antidiabetic agent.

US Patent Application, Publication Number US 2003/0187074 describes an oral delivery system comprising a biguanide, such as metformin
10 hydrochloride, which provides controlled release of the biguanide independent of environmental pH.

US Patent Numbers 6,475,521 and 6,660,300 describe controlled release delivery systems for pharmaceuticals having high water solubility, such as metformin hydrochloride.

15 Compound A and pharmaceutically acceptable salts or solvates thereof, in particular the maleate salt, are known to exhibit marked pH dependent solubility, *i.e.* they are more soluble in the acidic conditions of the stomach (around pH 2) than in the near neutral conditions of the lower intestine (around pH 7).

20 Certain antidiabetic agents, such as metformin, are known to have a narrow absorption window. It is therefore preferable that such agents are delivered substantially exclusively in a particular pharmacological environment, such as the stomach.

Thus, it is an object of the present invention to provide an oral dosage
25 which compensates for the pH dependent solubility of Compound A or a pharmaceutically acceptable salt or solvate thereof, and which compensates for the narrow absorption window of certain other antidiabetic agents, such as metformin, by providing delivery of the other antidiabetic agent substantially exclusively in a particular pharmacological environment, such as the stomach.
30 Such a dosage form is indicated to provide a beneficial effect on glycemic control for an extended period of time. Such a dosage form is also considered to be suitable for once daily administration.

Accordingly, in its broadest aspect the present invention provides an oral dosage form comprising an erodable core, which core comprises Compound A

or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, the core having a coating with one or more openings, characterised in that the coating is erodable under predetermined pH conditions.

The present invention further provides an oral dosage form comprising,
5 (i) an erodable core, which core comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent; and
(ii) an erodable coating around said core, which coating comprises one or more openings extending substantially completely through said coating but not substantially penetrating said core and communicating from the environment of
10 use to said core;
wherein release of Compound A or a pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent from the erodable core occurs substantially through the said opening(s) and through erosion of said erodable coating under pre-determined pH conditions.

15 Suitably, the dosage form is a tablet.

The above references to the core being erodable includes the situation where the core disintegrates partially or wholly, or dissolves, or becomes porous, on contact with an environmental fluid so as to allow the fluid to contact the active agent. Suitably, the core disintegrates partially. Suitably, the core
20 disintegrates wholly. Suitably, the core dissolves. Suitably, the core becomes porous.

While this invention provides that erosion of the coating is pH-dependent, the core may release Compound A or a pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent by eroding in a non-pH
25 dependent manner. However, to suit a specific demand, the core may be a material which allows pH dependent erosion or disintegration of the core to release Compound A or a pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent from its matrix.

In one embodiment, the core is formulated so as to be erodable to
30 substantially the same extent in both the stomach and the intestines.

The erodable core may be formulated to provide immediate or modified release of at least one of Compound A or a pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent. Suitably, the core is formulated to provide immediate release of both Compound A or a pharmaceutically

acceptable salt or solvate thereof and the other antidiabetic agent. In the alternative, the core is formulated to provide modified release of both Compound A or a pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent.

5 Suitable materials for the core include erodable polymethylmethacrylate resins such as the Eudragit™ series, for example Eudragit™ L30D, saccharoses, for example lactose and maltose, and cellulose esters, for example methylcellulose, hydroxypropylmethylcellulose (HPMC) and hydroxypropylcellulose, magnesium stearate, sodium starch glycolate and
10 povidone (polyvinylpyrrolidone). Suitably, the core is predominantly microcrystalline cellulose, hydroxypropylmethylcellulose, lactose and povidone. More suitably, the core consists essentially of hydroxypropylmethylcellulose, lactose, microcrystalline cellulose, sodium starch glycolate, povidone and magnesium stearate.

15 The above reference to the coating being erodable includes the situation where the coating disintegrates partially or wholly, or dissolves, or becomes porous, on contact with an environmental fluid so as to allow the fluid to contact the core. Suitably, the coating disintegrates partially. Suitably, the coating disintegrates wholly. Suitably, the coating dissolves. Suitably, the coating
20 becomes porous. Preferably, the erodable coating is an enteric coating, *i.e.* it has a defined, pre-determined pH threshold at which it dissolves. Preferably, the coating erodes at pH greater than 4.5. More preferably, the coating erodes in the pH range from 4.5 to 8. Most preferably, the coating erodes in the pH range 5 to 7. Preferably, the enteric coating is non-permeable.

25 The use of a coating that erodes rapidly on exiting the stomach environment has been found to be particularly beneficial where the other antidiabetic agent, such as metformin, has a narrow absorption window. In such circumstances any active agent that is not released in the stomach is rapidly delivered on entry into the small intestine, thereby minimising any loss in
30 absorption associated with delivery lower down the GI tract.

Materials and their blends suitable for use as a pH-dependent erodable coating material in this invention include various polymethacrylate polymers, co-processed polyvinylacetate phthalate, cellulose acetate trimellitate, cellulose

acetate phthalate, shellac, hydroxypropylmethylcellulose phthalate polymers and their copolymers. Suitably, the coating material is selected from cellulose acetate trimellitate (CAT), polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate 50, hydroxypropylmethylcellulose phthalate 55, Acryl-eze™, Aquateric™, cellulose acetate phthalate, Eudragit™ L30 D, Eudragit™ L, Eudragit™ S and shellac. Most preferably, the coating material is Eudragit™ L30 D.

When necessary, the erodable coating may be modified by addition of plasticisers or anti-tack agents. Suitable materials for this purpose include waxy materials such as glycerides, for example glyceryl monostearate.

Typical sizes for the opening(s), when circular, to be formed in the coating are in the range 0.5 mm – 8 mm of diameter, such as 1, 2, 3, 4, 5 or 6 mms in diameter, depending on the overall size of the tablet and the desired rate of release. The opening(s) may have any convenient geometrical shape, but a rounded shape, e.g. substantially circular or elliptical, is generally preferred. More elaborate shapes, such as text characters or graphics, may also be formed, provided that the release rate can be made uniform in individual dosage forms. Typical sizes of non-circular openings are equivalent in area to the above mentioned sizes for circular openings, thus in the range of from about 0.19 to about 50.3 mm².

For the purposes of the present invention, the term "opening" is synonymous with hole, aperture, orifice, passageway, outlet etc.

The opening(s) may be formed by methods disclosed in US 5,004,614. Typically opening(s) may be formed by drilling, for example using mechanical drill bits or laser beams, or by punches that remove the cut area. The formation of the opening(s) may by default remove a small portion of the exposed core. It is also possible to purposely form a cavity below the aperture as a release rate controlling device, the cavity exposing a greater initial surface area of core than a flat surface. Suitably, the opening(s) extend through the entire erodable coating such that there is immediate exposure of the core to the environmental fluid when the device is placed in the desired environment of use.

Also it is possible to form the opening(s) *in situ* when the dosage form is administered, by forming a coating containing pore-forming agents i.e. material

that will dissolve in the stomach to create pores in the coating. Accordingly, there is also provided an oral dosage form comprising,

(i) an erodable core, which core comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent; and

5 (ii) an erodable coating surrounding said core, which coating comprises a pore forming agent that is erodable in the pH range from 1 to 3 to form one or more openings extending substantially completely through said coating but not substantially penetrating said core and communicating from the environment of use to said core;

10 wherein release of Compound A or a pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent from the dosage form occurs through the said opening(s) by the erosion of said erodable core and through erosion of said erodable coating under pre-determined pH conditions.

In US 5,004,614, the opening(s) preferably comprise about 10 - 60 % of
15 the total face area of the tablet i.e. the upper and lower surfaces of a biconvex tablet. In the present invention, the opening(s) may comprise 0.25 to 70%, such as 10 - 70% of the total face area.

Alternatively, it may be useful to characterise the rate controlling effect of the opening(s) by reference to the area of the opening(s) relative to the total
20 surface area of the coated tablet. Additionally, especially in cases where the core erodes by undercutting of the edges of the opening(s), the rate controlling effect may be related to the total circumference of the opening(s).

An unexpected finding is that two openings, for example one on each primary surface of a biconvex tablet, release an active agent from the core at a
25 rate marginally greater than that of a single opening of the same overall area. It is also indicated that the variability of the release rate from the two openings is less than the variability of release rate from the corresponding single opening. Accordingly, in one embodiment of the invention, the coating of the core is provided with two or more openings. More preferably, the erodable coating
30 surrounding the core is provided with two openings extending substantially completely through said coating but not substantially penetrating said core and communicating from the environment of use to said core.

Where more than one opening is provided, the openings may be located on the same face of the oral dosage form, or on different surfaces. Suitably, the

oral dosage form has two openings, one on each opposing surface. Suitably, the oral dosage form is a tablet having two opposed primary surfaces, each surface having one opening through the coating.

As a protection for the core material, to prevent contamination via the opening(s) before dosing, it may be desirable to provide a conventional seal coating to either the core, or to the dosage form after formation of the opening(s). The seal coat may be a sub-coat or over-coat to the erodable coating.

Where the oral dosage form comprises an antidiabetic agent which is known to have a narrow absorption window, such as metformin, the dosage form is preferably formulated to provide delivery of the antidiabetic agent substantially exclusively in a particular pharmacological environment, such as the stomach. Where substantially exclusive delivery of the other antidiabetic agent in the stomach is required, the oral dosage form is suitably formulated to reside in the gastric environment over an extended period of time. Increased gastric retention times may be achieved, for example, by increasing the size of the dosage form, and/or administering the dosage form with food.

According to a further aspect of the present invention, there is provided a process for the preparation of an oral dosage form according to the present invention, which process comprises:

- (a) preparing an erodable tablet core comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent;
- (b) coating the core with a material with pH-dependent erodability; and
- (c) creating one or more openings in the coating.

According to yet a further aspect of the present invention there is provided a process for the preparation of an oral dosage form according to the present invention, which process comprises:

- (a) preparing an erodable tablet core comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent;
- (b) coating the core with a material with pH-dependent erodability; and
- (c) creating one or more openings in the coating, said opening(s) extending substantially completely through said coating but not substantially penetrating said core and communicating from the environment of use to said core.

The core may be prepared by compressing suitable ingredients to form a compacted mass, which comprises the core of the dosage form (also referred to herein as "tablet core"). This may be prepared using conventional tablet
5 excipients and formulation compression methods. Thus, the core typically comprises the active agents along with excipients that impart satisfactory processing and compression characteristics such as diluents, binders and lubricants. Additional excipients that may form part of the core of the device include disintegrants, flavourants, colorants, release modifying agents and/or
10 solubilising agents such as surfactants, pH modifiers and complexation vehicles.

Typically the active agents and excipients are thoroughly mixed prior to compression into a solid core. The core of the device may be formed by wet granulation methods, dry granulation methods or by direct compression. The core may be produced according to any desired pre-selected shape such as bi-
15 convex, hemi-spherical, near hemi-spherical, round, oval, generally ellipsoidal, oblong, generally cylindrical or polyhedral, e.g. a triangular prism shape. The term "near hemi-spherical" is intended to be construed in the manner described in US 5,004,614. Suitably the core is formulated into a bi-convex shape, e.g. having two domed opposite surfaces. In addition, the core may be produced in a
20 multi-layered (e.g. bi- or tri- layered) form. For example, the core may be formulated as a bilayer, in which one layer comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and the other layer comprises another antidiabetic agent.

The core may be coated with a suitable pH dependent erodable material
25 by any pharmaceutically acceptable coating method. Examples include coating methods disclosed in US 5,004,614 and film coating, sugar coating, spray coating, dip coating, compression coating, electrostatic coating. Typical methods include spraying the coating onto the tablet core in a rotating pan coater or in a fluidised bed coater until the desired coating thickness is achieved.
30 Suitably the coating is provided to add about 4 to 8 mg/ cm² or 5 - 7 mg/ cm² of dry polymer around the tablet surface area. Typically this results in an increase in weight (relative to the core) of from 3 – 10% or 5 – 10 % by weight. Suitably, the coating has a thickness in the range 0.05 to 0.5 mm.

As used herein, the term "modified release" means a composition which has been designed to produce a desired pharmacokinetic profile by choice of formulation. Modified release also includes modified release compositions in combination with non-modified release compositions. For example, the term
5 "modified release" shall comprise delayed, pulsed and sustained release either alone or in any combination.

In one aspect the modified release composition provides delayed release of at least one of Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent. Delayed release is conveniently
10 obtained by use of a gastric resistant formulation such as an enteric formulation. Such an enteric formulation may comprise multi-particulates, such as multi-particulate spheres, coated with a gastric resistant polymer. Suitable, gastric resistant polymers include polymers derived from methacrylates, cellulose acetate phthalate, polyvinyl acetate phthalate and hydroxypropyl methylcellulose
15 phtahlate. Examples of such polymers include Eudragit L100-55™ (Poly(methacrylic acid, ethyl acrylate) 1:1) for example as Eudragit L30D-55™ or Eudragit FS 30D™, Aquateric™ (cellulose acetate phthalate), Sureteric™ (polyvinyl acetate phthalate), HPMCP-HP-55S™ (hydroxypropyl methylcellulose phtahlate).

20 The multiparticulates include coated drug-coated non-pareil substrates, such as lactose spheres, or drug containing non-pareil substrates, such as drug containing lactose spheres. Such multiparticulates are coated as required with an appropriate enteric formulation, for example a polymethacrylate polymer. An example of a suitable polymethacrylate polymer is Eudragit L100-55™
25 (Poly(methacrylic acid, ethyl acrylate) 1:1), for example as Eudragit L30D-55™ or Eudragit FS 30D™.

In a further aspect the modified release composition provides sustained release of at least one of Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, for example providing release of
30 the active agent(s) over a time period of up to 26 hours; suitably in the range of 4 to 24 hours; preferably in the range of 12 to 24 hours.

Sustained release is typically provided by use of a sustained release matrix, usually in tablet form, such as disintegrating, non-disintegrating or eroding matrices.

Sustained release is suitably obtained by use of a non-disintegrating matrix tablet formulation. Suitable non disintegrating matrix tablet formulations are provided by the incorporation of methacrylates, cellulose acetates, carbomers and hydroxypropyl methylcellulose phtahlate into the tablet. Examples of suitable materials include Eudragit RS™ (Poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1), Eudragit RL™ (Poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.2), Carbopol 971P™ (carbomer), HPMCP-HP-55S™ (hydroxypropyl methylcellulose phtahlate).

Sustained release is further obtained by use of a disintegrating matrix tablet formulation, for example by incorporating methacrylates, methylcellulose or hydroxypropyl methylcellulose into the tablet. Examples of suitable materials include Eudragit L™ (Poly(methacrylic acid, ethyl acrylate) 1:1) and Methocel K4M™ (hydroxypropyl methylcellulose).

Sustained release can also be achieved by using multiparticulates coated with semipermeable membranes. The multiparticulates include coated drug-coated non-pareil substrates, such as lactose spheres, or drug containing substrates, such as drug containing lactose/Avicel™ (microcrystalline cellulose) spheres. Such multiparticulates are coated as required with the appropriate semi-permeable membranes, such as ethylcellulose polymer.

In yet a further aspect the modified release composition provides pulsed release of at least one of Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, for example providing up to 4, for example 2, pulses of active agent per 24 hours.

Suitable materials for an immediate release composition include saccharoses, for example lactose and maltose, and celluloses, for example microcrystalline cellulose. Most suitably, the immediate release composition is predominantly microcrystalline cellulose. More suitably, the immediate release composition consists essentially of lactose, microcrystalline cellulose and magnesium stearate.

As indicated above, the oral dosage form of the present invention is considered to be suitable for once daily administration and during use is indicated to provide a therapeutic effect over an extended period of time, such as up to 24 hours, for example, up to 12, 14, 16, 18, 20 and 24 hours, per unit dose.

5 A suitable dosage form of Compound A or a pharmaceutically acceptable salt or solvate thereof when used in accordance with the present invention is up to 12 mg, for example, 1 to 12 mg. Thus, suitable dosage forms comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

10 Particular dosage forms comprise 2 to 4 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

Particular dosage forms comprise 4 to 8 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

15 Particular dosage forms comprise 8 to 12 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

One dosage form comprises 2 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

Preferred dosage forms comprise 4 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

20 Preferred dosage forms comprise 8 mg of Compound A or a pharmaceutically acceptable salt or solvate thereof.

Suitable other antidiabetic agents according to the present invention include alpha glucosidase inhibitors, biguanides and insulin secretagogues.

25 A suitable alpha glucosidase inhibitor is acarbose. Other suitable alpha glucosidase inhibitors are emiglitate and miglitol. A further suitable alpha glucosidase inhibitor is voglibose.

Suitable biguanides include metformin, buformin or phenformin, especially metformin. A preferred pharmaceutically acceptable salt of metformin is the hydrochloride salt.

30 Suitable insulin secretagogues include sulphonylureas.

Suitable sulphonylureas include glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide. Further sulphonylureas include acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone,

glisentide, glisolamide, glisoxepide, glyclopyamide and glycylamide. Also included is the sulphonylurea glipentide.

Further suitable insulin secretagogues include repaglinide. An additional insulin secretagogue is nateglinide.

5 Suitable dosages, preferably unit dosages, of the other antidiabetic agent, such as the alpha glucosidase inhibitor, a biguanide or insulin secretagogue, include the known permissible doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The
10 Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.

For the alpha glucosidase inhibitor, a suitable amount of acarbose is in the range of from 25 to 600 mg, including 50 to 600 mg, for example 100 mg or
15 200 mg.

For the biguanide, a suitable dosage of metformin is between 100 to 3000 mg, for example 250, 500 mg, 850 mg or 1000 mg, especially 500 mg and 1000 mg.

For the insulin secretagogue, a suitable amount of glibenclamide is in the
20 range of from 2.5 to 20 mg, for example 10 mg or 20 mg; a suitable amount of glipizide is in the range of from 2.5 to 40 mg; a suitable amount of gliclazide is in the range of from 40 to 320 mg; a suitable amount of tolazamide is in the range of from 100 to 1000 mg; a suitable amount of tolbutamide is in the range of from 1000 to 3000 mg; a suitable amount of chlorpropamide is in the range of from
25 100 to 500 mg; and a suitable amount of gliquidone is in the range of from 15 to 180 mg. Also a suitable amount of glimepiride is 1 to 6 mg and a suitable amount of glipentide is 2.5 to 20 mg.

A suitable amount of repaglinide is in the range of from 0.5 mg to 20 mg, for example 16 mg. Also a suitable amount of nateglinide is 90 to 360 mg, for
30 example 270 mg.

Where the dosage form comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and metformin, particularly preferred fixed doses are 2 mg Compound A and 500 mg metformin; 4 mg Compound A and

500 mg metformin; 2 mg Compound A and 1000 mg metformin; 4 mg Compound A and 1000 mg metformin; and 8 mg Compound A and 1000 mg metformin.

By adjustment of the above variables and the surface area of the exposed core, the release rates in the different environmental conditions can be
5 harmonised to obtain comparable release rates under different body environments, and so achieve more constant dosing to a patient.

Preferably the dissolution rates of the oral dosage forms of this invention are arranged, for example by routine adjustment of the erodable coating and dimensions of the opening(s), so that the rate of release is substantially similar in
10 the different pH environments experienced by the dosage form on administration. Dissolution rates may be assessed by *in vitro* testing in solutions of the appropriate pHs. For example, when comparing dissolution in the stomach and intestine, tests may be carried out initially at pH 1.5 with a transfer to pH 6.8 after 2 hours or 4 hours, as an assumed time for residence in the
15 stomach before emptying into the intestines of a notional patient in respectively fasted and fed conditions. Alternatively, tests may be carried out initially at pH 4.0, to simulate a fed stomach environment, with a transfer to pH 6.8 after 5 hours.

As mentioned above, Compound A or a pharmaceutically acceptable salt
20 or solvate thereof when administered in an oral dosage form of this invention is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof; metabolic syndrome, impaired glucose tolerance and impaired fasting glucose (hereinafter referred to as the 'Disorders of the Invention'). Suitably, Compound
25 A or a pharmaceutically acceptable salt or solvate thereof when administered in an oral dosage form of this invention is indicated to be useful in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof. Suitably, Compound A or a pharmaceutically acceptable salt or solvate thereof when administered in an oral
30 dosage form of this invention is indicated to be useful in the treatment and/or prophylaxis of metabolic syndrome. Suitably, Compound A or a pharmaceutically acceptable salt or solvate thereof is indicated to be useful in the treatment and/or prophylaxis of impaired glucose tolerance. Suitably, Compound A or a pharmaceutically acceptable salt or solvate thereof when

administered in an oral dosage form of this invention is indicated to be useful in the treatment and/or prophylaxis of impaired fasting glucose.

In a preferred embodiment the present invention provides a method for the treatment and/or prophylaxis of the Disorders of the Invention which method
5 comprises administering an oral dosage form of this invention comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, to a human or non-human mammal in need thereof.

In a further preferred embodiment the present invention provides an oral dosage form of the invention comprising Compound A or a pharmaceutically
10 acceptable salt or solvate thereof and another antidiabetic agent for use in the treatment and/or prophylaxis of the Disorders of the Invention.

Suitable pharmaceutically acceptable forms of the other antidiabetic agent depend upon the particular agent used but included are known pharmaceutically acceptable forms of the particular agent chosen. Such
15 derivatives are found or are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and the above-mentioned publications. For example, a particular form of metformin is
20 metformin hydrochloride, a particular form of repaglinide is a benzoic acid salt form and a particular form of tolbutamide is a sodium salt form.

As used herein the term "pharmaceutically acceptable" embraces compounds, compositions and ingredients for both human and veterinary use. For example the term "pharmaceutically acceptable salt" embraces a veterinarily
25 acceptable salt. In particular, suitable pharmaceutically acceptable salted forms of Compound A include those described in European Patent Number 0 306 228 and International Patent Application, Publication Number WO 94/05659. A particularly preferred salt of Compound A is the maleate salt. A preferred pharmaceutically acceptable solvated form of Compound A is a hydrate.

30 As used herein, the term " C_{\max} " shall mean the mean maximum plasma level concentration.

As used herein the term "AUC" shall mean the mean area under the plasma concentration versus time curve over the dosing interval at steady state.

No adverse toxicological effects are indicated in the above mentioned treatments.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

In the following Examples, tablet cores were formed by conventional means by mixing together the active ingredients with excipients and compressing to form the tablet core. These Examples are intended to be by way of illustration rather than limitation of the present invention and the combination of Compound A and metformin is used simply as one example of a combination suitable for use with the present invention.

Example 1

A core was formed from the following formulation:

	%w/w
<u>Immediate Release Layer</u>	
Compound A (as maleate salt)	0.5
Compound B (as hydrochloride salt)	85.2
Lactose Monohydrate	1.9
Microcrystalline cellulose	5.6
Magnesium stearate	0.5
Hypromellose (HPMC)	3.6
Sodium starch glycolate	0.2
Povidone	2.6

by compression to form a 19.0mm x 9.2mm, oval tablet of 1174 mg.

The tablet cores were coated with a HPMC-based sub-coat and a polymethacrylate resin soluble at pH 5.5 to a total weight of 1246.5 mg.

An opening of diameter 3.0 mm was drilled through the coating in each of the two primary surfaces of the coated cores to expose the surface of the core.

Example 2

A core was formed from the following formulation:

	%w/w
<u>Immediate Release Layer</u>	
5 Compound A (as maleate salt)	0.5
Compound B (as hydrochloride salt)	85.2
Lactose Monohydrate	1.9
Microcrystalline cellulose	5.6
Magnesium stearate	0.5
10 Hypromellose (HPMC)	3.6
Sodium starch glycolate	0.2
Povidone	2.6

by compression to form a 19.0mm x 9.2mm, oval tablet of 1174 mg.

15

The tablet cores were coated with a HPMC-based sub-coat and a polymethacrylate resin soluble at pH 5.5 to a total weight of 1246.5 mg.

20 An opening of diameter 4.0 mm was drilled through the coating in each of the two primary surfaces of the coated cores to expose the surface of the core.

25 Dissolution profiles for the dosage forms of Examples 1 and 2, for Compound A and metformin ('Compound B') are shown in Figures 1 and 2 respectively in the accompanying drawings. Dissolution tests were performed initially at pH 4.0, with a transfer to pH 6.8 after 5 hours.

30

A Study to Estimate the Pharmacokinetics of Six Extended Release Formulations of AVANDAMET™ (rosiglitazone maleate 4 mg/metformin HCl 1000 mg), Compared to the Commercial Formulation of AVANDAMET™ (rosiglitazone maleate 2 mg/metformin HCl 500 mg, given twice daily), and Concomitant Dosing of Glucophage XR (metformin HCl 2 x 500 mg) with AVANDIA™ (rosiglitazone maleate 4 mg)

Primary Objectives

To compare the single dose pharmacokinetics of six extended release formulations of AVANDAMET™ (rosiglitazone maleate 4 mg/metformin HCl 1000 mg) to those of the commercial formulation of AVANDAMET™ (rosiglitazone maleate 2 mg/metformin HCl 500 mg, given twice daily).

To compare the single dose pharmacokinetics of six extended release formulations of AVANDAMET™ (rosiglitazone maleate 4 mg/metformin HCl 1000 mg) to those of concomitantly dosed Glucophage XR (metformin HCl 2 x 500 mg) with AVANDIA™ (rosiglitazone maleate 4 mg).

Secondary Objectives

To assess the safety and tolerability of single oral doses of each of the six extended release formulations of AVANDAMET™ (rosiglitazone maleate 4 mg/metformin HCl 1000 mg); currently marketed formulation of AVANDAMET™ (rosiglitazone maleate 2 mg/metformin 500 mg, given twice daily); and concomitant dosing of Glucophage XR (metformin hydrochloride 2 x 500 mg) with AVANDIA™ (rosiglitazone maleate 4 mg) commercial tablets.

To compare the pharmacokinetics of the currently marketed formulation of AVANDAMET™ (rosiglitazone maleate 2 mg/metformin HCl 500 mg, given twice daily) to concomitantly dosed Glucophage XR (metformin HCl 2 x 500 mg) with AVANDIA™ (rosiglitazone maleate 4 mg).

Study Design

This was a randomized, open-label, four-period, period-balanced crossover study with three parallel groups conducted in healthy volunteers. Each subject participated in four study sessions separated by a washout period of at least 7
5 days. In each study session, subjects were randomized to receive either a single oral dose of AVANDAMET™, AVANDIA™ plus Glucophage XR, or two of six extended release formulations of AVANDAMET™ in the evening under fed conditions.

Number and nature of subjects

10 Fifty-one subjects were enrolled in the study and thirty-nine subjects completed the study. Subjects were healthy adult males and females between 18 and 65 years of age, inclusive, with body weight > 50 kg (110 lbs) and Body mass index (BMI) between 19 and 30 kg/m².

Criteria for evaluation

15 Plasma specimens for rosiglitazone and metformin pharmacokinetic analysis were obtained prior to study medication administration in each session and over a 24-hour interval. Plasma concentration-time data were analyzed for rosiglitazone and metformin. The following pharmacokinetic parameters were determined, if data permitted: maximum observed plasma concentration (C_{max}),
20 time to C_{max} (t_{max}), area under the plasma concentration-time curve to the last measurable concentration (AUC(0-t)), (AUC(0-36h)), and extrapolated to infinity (AUC(0-inf)), and half-life (t_{1/2}).

Safety and tolerability were assessed by adverse events, clinical laboratory evaluations (hematology, clinical chemistry and urinalysis), vital signs (semi-
25 recumbent blood pressure, heart rate), 12-lead ECG and concurrent medications. All subjects who received at least one dose of study medication were included in the evaluation of clinical safety and tolerability.

Pharmacokinetic Results

Geometric Mean (Range) Metformin Pharmacokinetic Parameters:

Regimen	C _{max} , ng/mL	AUC(0-∞), ng.h/mL	AUC(0-t), ng.h/mL	T _{max} ¹ , h	t _{1/2} , h
A: Commercial Avandamet, bid	895 (565-1404)	12330 (8868-18388)	12010 (8353-18070)	3.48 (1.50-6.00)	4.24 (2.81-5.98)
B: Avandia+Glucophage XR	1140 (412-2189)	11904 (3252-20741)	11614 (2993-20560)	6.00 (2.50-10.00)	5.63 (2.99-10.65)
C: Extended Release #1 (rosiglitazone 4mg / metformin 1000 mg)	1074 (478-1845)	9357 (4923-14160)	8788 (4738-13992)	10.00 (1.00-12.02)	5.16 (4.33-7.00)
D: Extended Release #2 (rosiglitazone 4mg / metformin 1000 mg)	1308 (940-1928)	11178 (8573-15499)	10787 (8191-15311)	8.00 (5.00-10.00)	5.27 (2.74-7.29)
E: Extended Release #3 (rosiglitazone 4mg / metformin 1000 mg)	1382 (1016-1751)	12995 (10116-16212)	12727 (9991-15995)	8.00 (2.80-10.00)	4.87 (2.74-6.45)
F: Extended Release #4 (rosiglitazone 4mg / metformin 1000 mg)	1372 (817-2447)	12527 (7307-21615)	12325 (7191-21339)	8.00 (4.00-10.35)	4.99 (3.41-6.72)
G: Extended Release #5 (rosiglitazone 4mg / metformin 1000 mg)	1472 (911-1472)	13492 (8529-18214)	12926 (8201-17903)	6.00 (5.00-10.00)	5.69 (3.01-9.20)
H: Extended Release #6 (rosiglitazone 4mg / metformin 1000 mg)	1363 (1010-2045)	12440 (9206-19061)	12235 (9061-18715)	6.00 (3.00-8.00)	5.57 (3.04-9.24)

- 5 The plasma AUC observed for Compound A (rosiglitazone maleate) generated from Extended Release formulation #3 was equivalent to the rosiglitazone AUC from the reference regimens (i.e. A and B). Similarly, the plasma metformin AUC observed generated from Extended Release formulation #3 was equivalent
- 10 to the metformin AUC from the reference regimens (i.e. A and B). Similar extended-release plasma concentration profiles were observed for both active agents. After administration of the extended release formulation #3, the observed inter-subject variability of rosiglitazone and metformin pharmacokinetic parameters was consistent with the reference treatment groups (regimens A and
- 15 B).

Conclusion

A once-a-day modified release tablet formulation comprising Compound A and metformin has been identified that on administration provides equivalent area under the plasma concentration versus time curve (after a single-dose)
5 compared to the AUC observed after administration of the immediate release tablet formulation comprising Compound A and metformin (given bid x 2 doses). Furthermore, AUC equivalence was demonstrated between the modified release formulation (rosiglitazone and metformin) compared to a single dose of concomitantly administered rosiglitazone and glucophage XR.

10

15

20

Claims

- 5 1. An oral dosage form comprising an erodable core which comprises 5-[4-
[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a
pharmaceutically acceptable salt or solvate thereof and another
antidiabetic agent, the core having a coating with one or more openings
leading to the core, characterised in that the coating is erodable under
10 predetermined pH conditions.
2. An oral dosage form according to claim 1, comprising,
(i) an erodable core, which core comprises Compound A or a
pharmaceutically acceptable salt or solvate thereof and another
15 antidiabetic agent; and
(ii) an erodable coating around said core, which coating comprises one or
more openings extending substantially completely through said coating
but not substantially penetrating said core and communicating from the
environment of use to said core;
20 wherein release of Compound A or a pharmaceutically acceptable salt or
solvate thereof and the other antidiabetic agent from the erodable core
occurs substantially through the said opening(s) and through erosion of
said erodable coating under pre-determined pH conditions.
- 25 3. An oral dosage form according to claim 1 or claim 2, wherein the erodable
coating an enteric coating.
4. An oral dosage form according to claim 3, wherein the enteric coating is
non-permeable.
30 5. An oral dosage form according to claim 1, wherein the erodable core is
formulated to provide immediate release of both Compound A or a

pharmaceutically acceptable salt or solvate thereof and the other antidiabetic agent.

5 6. An oral dosage form according to claim 1, wherein said other antidiabetic agent is metformin or a pharmaceutically acceptable salt or solvate thereof.

10 7. An oral dosage form according to any preceding claim, wherein said dosage form is a tablet form.

8. According to a further aspect of the present invention, there is provided a process for the preparation of an oral dosage form according to claim 1, which process comprises:


- 15 (a) preparing an erodable tablet core comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent;
- (b) coating the core with a material with pH-dependent erodability; and
- (c) creating one or more openings in the coating.

20 9. A method for the treatment and/or prophylaxis of the Disorders of the Invention which method comprises administering an oral dosage form comprising Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, according to claim 1, to a human or non-human mammal in need thereof.

25


30

1/2

Fig. 1Dissolution Profiles for Examples 1 and 2 -
Compound A

2/2

Fig. 2

Dissolution Profiles for Examples 1 and 2 -
Compound B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/008970

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/155 A61K31/4439 A61K9/28 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 099 862 A (CHENG XIU XIU ET AL) 8 August 2000 (2000-08-08) cited in the application example 1	1-9
Y	WO 01/35940 A (LEWIS KAREN ; LILLOTT NICOLA JAYNE (GB); MACKENZIE DONALD COLIN (GB);) 25 May 2001 (2001-05-25) claims 1-14	1-9
Y	WO 01/82867 A (AEROPHARM TECHNOLOGY INC) 8 November 2001 (2001-11-08) claims 1-18	1-9
A	EP 0 365 123 A (FORUM CHEMICALS LTD) 25 April 1990 (1990-04-25) cited in the application page 3, column 4, lines 2-11	1-9
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

10 November 2004

Date of mailing of the international search report

26/11/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Young, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT /EP2004/008970

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	<p>WO 03/068195 A (MARTINI LUIGI ; RE VINCENZO (GB); GLAXO GROUP LTD (GB); LI CHI LEUNG () 21 August 2003 (2003-08-21) examples 1,2 claims 1-13</p> <p>-----</p>	1-9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/008970

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 9 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/008970

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6099862	A	08-08-2000	AT 269709 T	15-07-2004
			AU 749550 B2	27-06-2002
			CA 2341908 A1	09-03-2000
			DE 69918310 D1	29-07-2004
			EP 1107763 A1	20-06-2001
			WO 0012097 A1	09-03-2000
			US 6284275 B1	04-09-2001
WO 0135940	A	25-05-2001	AU 1403501 A	30-05-2001
			EP 1231917 A2	21-08-2002
			WO 0135940 A2	25-05-2001
			JP 2003514011 T	15-04-2003
WO 0182867	A	08-11-2001	AU 5745601 A	12-11-2001
			CA 2407713 A1	08-11-2001
			EP 1278513 A2	29-01-2003
			JP 2004516234 T	03-06-2004
			WO 0182867 A2	08-11-2001
EP 0365123	A	25-04-1990	AT 110262 T	15-09-1994
			AU 4218489 A	23-03-1990
			CA 1339079 C	29-07-1997
			DE 68917677 D1	29-09-1994
			DE 68917677 T2	22-12-1994
			EP 0365123 A1	25-04-1990
			ES 2058543 T3	01-11-1994
			WO 9001925 A1	08-03-1990
			GB 2222948 A , B	28-03-1990
			IE 63764 B1	14-06-1995
			US 5004614 A	02-04-1991
WO 03068195	A	21-08-2003	CA 2475544 A1	21-08-2003
			EP 1474114 A1	10-11-2004
			WO 03068195 A1	21-08-2003